Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
Pharmacology update from ONS 2019

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 477
Rating:

Teresa Knoop - Vanderbilt Ingram Cancer Center, Brentwood, USA

Teresa Knoop speaks to ecancer at ONS 2019 about newly FDA approved drugs from 2018 and 2019 thus far, as well as previously approved drugs with new indications.

She highlights some of the trends she has seen from this period - such as biosimilars, immunology, molecularly targeted therapies, cellular agents, radiopharmaceuticals and tumour agnostic drugs.

Teresa offers advice to oncology nurses who may feel overwhelmed by the large number of newly approved drugs each year, including learning about generic naming.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation